Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept

被引：3

作者：

Bewersdorf, Jan Philipp ^{[1
]}

Tallman, Martin S. ^{[2
]}

Stahl, Maximilian ^{[3
]}

机构：

[1] Yale Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT USA

[2] Mem Sloan Kettering Canc Ctr, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[3] Dana Farber Canc Inst, Dept Med Oncol, Adult Leukemia Program, Boston, MA 02215 USA

来源：

CURRENT OPINION IN ONCOLOGY | 2021年 / 33卷 / 06期

关键词：

acute myeloid leukemia; FLT3; inhibitors; hypomethylating agents; maintenance therapy; measurable residual disease; STEM-CELL TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIA; COMPLETE REMISSION; SORAFENIB MAINTENANCE; DOSE CYTARABINE; FREE SURVIVAL; GROUP-B; AML; CHEMOTHERAPY; INDUCTION;

D O I：

10.1097/CCO.0000000000000778

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of review Disease relapse remains the major cause of death in patients with acute myeloid leukemia (AML) and is driven by the persistence of leukemic cells following induction chemotherapy or allogeneic hematopoietic cell transplant (allo-HCT). Maintenance therapies to extend the duration of remission and to improve survival have been proposed for several years with mixed results but have experienced a renaissance recently. Recent findings The oral hypomethylating agent CC-486 has been the first agent to show an overall survival (OS) benefit compared with observation in AML patients in remission following intensive chemotherapy who are not proceeding to allo-HCT. In the realm of maintenance therapy following allo-HCT, the FLT3 inhibitor sorafenib has yielded superior results in terms of OS and relapse-free survival in randomized trials compared with observation. Several open questions remain regarding patient selection, timing, duration and safety of maintenance therapies. Various targeted agents are currently tested in clinical trials and could potentially enable an even more individualized therapeutic approach. Maintenance therapies following intensive chemotherapy or allo-HCT offer a new therapeutic paradigm for an increasing number of AML patients and have been shown to result in an OS benefit in selected patients.

引用

页码：658 / 669

页数：12

共 76 条

[51] Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML [J].

Perl, A. E. ;

Martinelli, G. ;

Cortes, J. E. ;

Neubauer, A. ;

Berman, E. ;

Paolini, S. ;

Montesinos, P. ;

Baer, M. R. ;

Larson, R. A. ;

Ustun, C. ;

Fabbiano, F. ;

Erba, H. P. ;

Di Stasi, A. ;

Stuart, R. ;

Olin, R. ;

Kasner, M. ;

Ciceri, F. ;

Chou, W-C ;

Podoltsev, N. ;

Recher, C. ;

Yokoyama, H. ;

Hosono, N. ;

Yoon, S-S ;

Lee, J-H ;

Pardee, T. ;

Fathi, A. T. ;

Liu, C. ;

Hasabou, N. ;

Liu, X. ;

Bahceci, E. ;

Levis, M. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (18) :1728-1740

[52] Maintenance Therapy With Interleukin-2 for Childhood AML Results of ELAM02 Phase III Randomized Trial [J].

Petit, Arnaud ;

Ducassou, Stephane ;

Leblanc, Thierry ;

Pasquet, Marlene ;

Rousseau, Alexandra ;

Ragu, Christine ;

Cachanado, Marine ;

Nelken, Brigitte ;

Bertrand, Yves ;

Michel, Gerard ;

Gandemer, Virginie ;

Cuccuini, Wendy ;

Fenneteau, Odile ;

Lapillonne, Helene ;

Auvrignon, Anne ;

Baruchel, Andre ;

Leverger, Guy .

HEMASPHERE, 2018, 2 (06)

[53] Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial [J].

Platzbecker, Uwe ;

Middeke, Jan Moritz ;

Sockel, Katja ;

Herbst, Regina ;

Wolf, Dominik ;

Baldus, Claudia D. ;

Oelschlagel, Uta ;

Mutherig, Anke ;

Fransecky, Lars ;

Noppeney, Richard ;

Bug, Gesine ;

Goetze, Katharina S. ;

Kraemer, Alwin ;

Bochtler, Tilmann ;

Stelljes, Matthias ;

Groth, Christoph ;

Schubert, Antje ;

Mende, Marika ;

Stoelzel, Friedrich ;

Borkmann, Christin ;

Kubasch, Anne Sophie ;

von Bonin, Malte ;

Serve, Hubert ;

Haenel, Mathias ;

Duehrsen, Ulrich ;

Schetelig, Johannes ;

Roellig, Christoph ;

Kramer, Michael ;

Ehninger, Gerhard ;

Bornhaeuser, Martin ;

Thiede, Christian .

LANCET ONCOLOGY, 2018, 19 (12) :1668-1679

[54] A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation [J].

Pratz, Keith W. ;

Rudek, Michelle A. ;

Smith, B. Douglas ;

Karp, Judith ;

Gojo, Ivana ;

Dezern, Amy ;

Jones, Richard J. ;

Greer, Jackie ;

Gocke, Christopher ;

Baer, Maria R. ;

Duong, Vu H. ;

Rosner, Gary ;

Zahurak, Marianna ;

Wright, John J. ;

Emadi, Ashkan ;

Levis, Mark .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (02) :300-306

[55]

PREISLER H, 1987, BLOOD, V69, P1441

[56] CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial [J].

Roboz, Gail J. ;

Ravandi, Farhad ;

Wei, Andrew H. ;

Dombret, Herve ;

Dohner, Hartmut ;

Thol, Felicitas ;

Voso, Maria Teresa ;

Schuh, Andre C. ;

Porkka, Kimmo ;

La Torre, Ignazia ;

Skikne, Barry ;

Kumar, Keshava ;

Dong, Qian ;

Beach, C. L. ;

Risueno, Alberto ;

De Menezes, Daniel Lopes ;

Ossenkoppele, Gert .

BLOOD, 2020, 136

[57] Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial [J].

Rollig, Christoph ;

Serve, Hubert ;

Huettmann, Andreas ;

Noppeney, Richard ;

Mueller-Tidow, Carsten ;

Krug, Utz ;

Baldus, Claudia D. ;

Brandts, Christian H. ;

Kunzmann, Volker ;

Einsele, Hermann ;

Kraemer, Alwin ;

Schaefer-Eckart, Kerstin ;

Neubauer, Andreas ;

Burchert, Andreas ;

Giagounidis, Aristoteles ;

Krause, Stefan W. ;

Mackensen, Andreas ;

Aulitzky, Walter ;

Herbst, Regina ;

Haenel, Mathias ;

Kiani, Alexander ;

Frickhofen, Norbert ;

Kullmer, Johannes ;

Kaiser, Ufrich ;

Link, Hartmut ;

Geer, Thomas ;

Reiche, Albert ;

Junghanss, Christian ;

Repp, Roland ;

Heits, Frank ;

Duerk, Heinz ;

Hase, Jana ;

Klut, Ina-Maria ;

Illmer, Thomas ;

Bornhaeuser, Martin ;

Schaich, Markus ;

Parmentier, Stefani ;

Goerner, Martin ;

Thiede, Christian ;

von Bonin, Malte ;

Schetelig, Johannes ;

Kramer, Michael ;

Berdel, Welfgang E. ;

Ehninger, Gerhard .

LANCET ONCOLOGY, 2015, 16 (16) :1691-1699

[58] Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies [J].

Savona, Michael R. ;

Kolibaba, Kathryn ;

Conkling, Paul ;

Kingsley, Edwin C. ;

Becerra, Carlos ;

Morris, John C. ;

Rifkin, Robert M. ;

Laille, Eric ;

Kellerman, Amy ;

Ukrainskyj, Stacey M. ;

Dong, Qian ;

Skikne, Barry S. .

AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (10) :1199-1206

[59] Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD [J].

Schlenk, Richard F. ;

Weber, Daniela ;

Fiedler, Walter ;

Salih, Helmut R. ;

Wulf, Gerald ;

Salwender, Hans ;

Schroeder, Thomas ;

Kindler, Thomas ;

Luebber, Michael ;

Wolf, Dominik ;

Westermann, Joerg ;

Kraemer, Doris ;

Goetze, Katharina S. ;

Horst, Heinz-August ;

Krauter, Juergen ;

Girschikofsky, Michael ;

Ringhoffer, Mark ;

Suedhoff, Thomas ;

Held, Gerhard ;

Derigs, Hans-Guenter ;

Schroers, Roland ;

Greil, Richard ;

Griesshammer, Martin ;

Lange, Elisabeth ;

Burchardt, Alexander ;

Martens, Uwe ;

Hertenstein, Bernd ;

Marretta, Lore ;

Heuser, Michael ;

Thol, Felicitas ;

Gaidzik, Verena, I ;

Herr, Wolfgang ;

Krzykalla, Julia ;

Benner, Axel ;

Doehner, Konstanze ;

Ganser, Arnold ;

Paschka, Peter ;

Doehner, Hartmut .

BLOOD, 2019, 133 (08) :840-851

[60] Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party [J].

Schuurhuis, Gerrit J. ;

Heuser, Michael ;

Freeman, Sylvie ;

Bene, Marie-Christine ;

Buccisano, Francesco ;

Cloos, Jacqueline ;

Grimwade, David ;

Haferlach, Torsten ;

Hills, Robert K. ;

Hourigan, Christopher S. ;

Jorgensen, Jeffrey L. ;

Kern, Wolfgang ;

Lacombe, Francis ;

Maurillo, Luca ;

Preudhomme, Claude ;

van der Reijden, Bert A. ;

Thiede, Christian ;

Venditti, Adriano ;

Vyas, Paresh ;

Wood, Brent L. ;

Walter, Roland B. ;

Doehner, Konstanze ;

Roboz, Gail J. ;

Ossenkoppele, Gert J. .

BLOOD, 2018, 131 (12) :1275-1291

← 1 2 3 4 5 6 7 8 →